Clinical trial · Observational
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
NCT06325826CI-TRIAL-00075431unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| General Evaluation Score (GES) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- interventionNames
- Diagnostic Test: General Evaluation Score (GES)
Primary outcomes (1)
- measure
- Hepatocellular Carcinoma
- timeFrame
- 24 month
- description
- Number of Participants develop New Hepatocellular Carcinoma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients aged 18 years or older. * Patients with compensated advanced chronic liver disease (cACLD) according to Baveno VI consensus (F3-F4) * achieved SVR for HCV after DAAs. Exclusion Criteria: * Previous interferon (IFN) treatment. * Hepatitis B virus (HBV) or human immune-deficiency virus (HIV) co-infection. * Current hepatocellular carcinoma (HCC) or other malignancies. * Previous history of HCC or HCC intervention. * Liver cell failure, liver transplantation or renal impairment
References
Publications (0)
Data not yet available
No reference posted for this study.